Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Rochester General Hospital
mi
from
Rochester, NY
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Rochester General Hospital
mi
from
Rochester, NY
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Strong Memorial Hospital
mi
from
Rochester, NY
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Strong Memorial Hospital
mi
from
Rochester, NY
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Presbyterian Hospital
mi
from
Charlotte, NC
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Presbyterian Hospital
mi
from
Charlotte, NC
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Lebauer Cardiovascular Research Foundation at Moses Cone Hospital
mi
from
Greensboro, NC
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Lebauer Cardiovascular Research Foundation at Moses Cone Hospital
mi
from
Greensboro, NC
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Clinical Research of Winston-Salem
mi
from
Winston-Salem, NC
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Clinical Research of Winston-Salem
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Toledo Hospital
mi
from
Toledo, OH
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Toledo Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Medical University of Ohio
mi
from
Toledo, OH
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Medical University of Ohio
mi
from
Toledo, OH
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Northshore Clinical Associates
mi
from
Erie, PA
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Northshore Clinical Associates
mi
from
Erie, PA
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Westmoreland Neurology Associates, Inc.
mi
from
Greensburg, PA
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Westmoreland Neurology Associates, Inc.
mi
from
Greensburg, PA
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Miriam Hospital
mi
from
Providence, RI
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Beaufort Memorial Hospital
mi
from
Beaufort, SC
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Beaufort Memorial Hospital
mi
from
Beaufort, SC
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Methodist University Hospital
mi
from
Memphis, TN
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Methodist University Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Brackenridge Hospital
mi
from
Austin, TX
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Brackenridge Hospital
mi
from
Austin, TX
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Seton Medical Center
mi
from
Austin, TX
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Seton Medical Center
mi
from
Austin, TX
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Methodist Hospital - The Neurological Institute
mi
from
Houston, TX
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Methodist Hospital - The Neurological Institute
mi
from
Houston, TX
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
University of Texas Health Sciences Center
mi
from
San Antonio, TX
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
University of Texas Health Sciences Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Virginia Commonwealth University
mi
from
Richmond, VA
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Neurological Consultants of Virginia Beach
mi
from
Virginia Beach, VA
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Neurological Consultants of Virginia Beach
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Harborview Medical Center
mi
from
Seattle, WA
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Harborview Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Madigan Army Medical Center
mi
from
Tacoma, WA
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Madigan Army Medical Center
mi
from
Tacoma, WA
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
St. Luke's Medical Center
mi
from
Milwaukee, WI
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
St. Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Medical College of Wisconsin
mi
from
Milwaukee, WI
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated:  12/21/2009
Gosford Hospital Department of Neurology
mi
from
Gosford,
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Status: Enrolling
Updated: 12/21/2009
Gosford Hospital Department of Neurology
mi
from
Gosford,
Click here to add this to my saved trials
The Comparison of the Necessity of Repeat Myocardial Perfusion SPECT Studies Between Tc-99m Tetro and Tc-99m Mibi
The Comparison of the Necessity of Repeat Myocardial Perfusion SPECT Studies Between Tc-99m Tetrofosmin and Tc-99m Sestamibi
Status: Enrolling
Updated:  1/11/2010
Cardiac Imaging of Augusta
mi
from
Augusta, GA
The Comparison of the Necessity of Repeat Myocardial Perfusion SPECT Studies Between Tc-99m Tetro and Tc-99m Mibi
The Comparison of the Necessity of Repeat Myocardial Perfusion SPECT Studies Between Tc-99m Tetrofosmin and Tc-99m Sestamibi
Status: Enrolling
Updated: 1/11/2010
Cardiac Imaging of Augusta
mi
from
Augusta, GA
Click here to add this to my saved trials
Carotid Atherosclerotic Plaque Study
Carotid Atherosclerotic Plaque Study
Status: Enrolling
Updated:  1/12/2010
University of Wisconsin
mi
from
Madison, WI
Carotid Atherosclerotic Plaque Study
Carotid Atherosclerotic Plaque Study
Status: Enrolling
Updated: 1/12/2010
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Same Day Discharge After Coronary Stenting Trial
Same Day Discharge After Coronary Stenting Trial
Status: Enrolling
Updated:  1/21/2010
University of Southern California
mi
from
Los Angeles, CA
Same Day Discharge After Coronary Stenting Trial
Same Day Discharge After Coronary Stenting Trial
Status: Enrolling
Updated: 1/21/2010
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Preventing Weight Gain and Controlling Blood Pressure During Smoking Cessation in Hypertensive Smokers
Blood Pressure Control in Hypertensive Smokers
Status: Enrolling
Updated:  1/22/2010
University of Iowa, Carver College of Medicine, Department of Internal Medicine, Division of General Internal Medicine
mi
from
Iowa City, IA
Preventing Weight Gain and Controlling Blood Pressure During Smoking Cessation in Hypertensive Smokers
Blood Pressure Control in Hypertensive Smokers
Status: Enrolling
Updated: 1/22/2010
University of Iowa, Carver College of Medicine, Department of Internal Medicine, Division of General Internal Medicine
mi
from
Iowa City, IA
Click here to add this to my saved trials
Preventing Weight Gain and Controlling Blood Pressure During Smoking Cessation in Hypertensive Smokers
Blood Pressure Control in Hypertensive Smokers
Status: Enrolling
Updated:  1/22/2010
Mayo Clinic College of Medicine
mi
from
Rochester, MN
Preventing Weight Gain and Controlling Blood Pressure During Smoking Cessation in Hypertensive Smokers
Blood Pressure Control in Hypertensive Smokers
Status: Enrolling
Updated: 1/22/2010
Mayo Clinic College of Medicine
mi
from
Rochester, MN
Click here to add this to my saved trials
Family Research Study: Metabolism of Fats and Proteins in Specific Ethnic Groups
Regulation of Lipoprotein(a) Metabolism in Humans With Reference to Ethnicity
Status: Enrolling
Updated:  2/1/2010
UC Davis CTSC Clinical Research Center (CCRC) at Veterans Affair Medical Center
mi
from
Mather, CA
Family Research Study: Metabolism of Fats and Proteins in Specific Ethnic Groups
Regulation of Lipoprotein(a) Metabolism in Humans With Reference to Ethnicity
Status: Enrolling
Updated: 2/1/2010
UC Davis CTSC Clinical Research Center (CCRC) at Veterans Affair Medical Center
mi
from
Mather, CA
Click here to add this to my saved trials
The Saint Francis Remote Ischemic Preconditioning Trial (SaFR)
The Saint Francis Remote Ischemic Preconditioning Trial (SaFR)
Status: Enrolling
Updated:  3/1/2010
St. Francis Hospital-The Heart Center
mi
from
Roslyn, NY
The Saint Francis Remote Ischemic Preconditioning Trial (SaFR)
The Saint Francis Remote Ischemic Preconditioning Trial (SaFR)
Status: Enrolling
Updated: 3/1/2010
St. Francis Hospital-The Heart Center
mi
from
Roslyn, NY
Click here to add this to my saved trials
Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia
Effects of Prescription OMega-3 Fatty Acids (Omacor®, Lovaza®) on Platelet Activity in Patients With Coronary Artery Disease With Hypertriglyceridemia (OMPA-CAD)
Status: Enrolling
Updated:  3/11/2010
Victor Serebruany
mi
from
Towson, MD
Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia
Effects of Prescription OMega-3 Fatty Acids (Omacor®, Lovaza®) on Platelet Activity in Patients With Coronary Artery Disease With Hypertriglyceridemia (OMPA-CAD)
Status: Enrolling
Updated: 3/11/2010
Victor Serebruany
mi
from
Towson, MD
Click here to add this to my saved trials
Clinical Proteomic Research for the Brain
Clinical Proteomic Research for the Brain
Status: Enrolling
Updated:  4/30/2010
Clinical Proteomic Research Center, Department of Neurology, ACC720, 55 Fruit Street, Massachusetts General Hospital
mi
from
Boston, MA
Clinical Proteomic Research for the Brain
Clinical Proteomic Research for the Brain
Status: Enrolling
Updated: 4/30/2010
Clinical Proteomic Research Center, Department of Neurology, ACC720, 55 Fruit Street, Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Global Vascular Effects of Intermittent Pneumatic Compression-Pilot Study
Global Vascular Effects of Intermittent Pneumatic Compression-Pilot Study
Status: Enrolling
Updated:  5/27/2010
Johns Hopkins Bayview Medical Center
mi
from
Baltimore, MD
Global Vascular Effects of Intermittent Pneumatic Compression-Pilot Study
Global Vascular Effects of Intermittent Pneumatic Compression-Pilot Study
Status: Enrolling
Updated: 5/27/2010
Johns Hopkins Bayview Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis
Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis
Status: Enrolling
Updated:  5/28/2010
Rady Children's Hospital Dermatolgoy
mi
from
San Diego, CA
Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis
Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis
Status: Enrolling
Updated: 5/28/2010
Rady Children's Hospital Dermatolgoy
mi
from
San Diego, CA
Click here to add this to my saved trials
Aleskiren Effect on Plaque Progression Using 3-dimensional Magnetic Resonance Imaging (3D MRI)
Aliskerin Effect on Plaque Progression in Established Atherosclerosis Using High Resolution 3D MRI: A Double Blind Placebo Controlled Trial
Status: Enrolling
Updated:  7/16/2010
OSU Davis Heart and Lung Research Institute
mi
from
Columbus, OH
Aleskiren Effect on Plaque Progression Using 3-dimensional Magnetic Resonance Imaging (3D MRI)
Aliskerin Effect on Plaque Progression in Established Atherosclerosis Using High Resolution 3D MRI: A Double Blind Placebo Controlled Trial
Status: Enrolling
Updated: 7/16/2010
OSU Davis Heart and Lung Research Institute
mi
from
Columbus, OH
Click here to add this to my saved trials
Inflammation and Vascular Function in Atherosclerosis
Inflammation and Vascular Function in Atherosclerosis
Status: Enrolling
Updated:  7/22/2010
Brigham and Women's Hosp
mi
from
Boston, MA
Inflammation and Vascular Function in Atherosclerosis
Inflammation and Vascular Function in Atherosclerosis
Status: Enrolling
Updated: 7/22/2010
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluation Cardiac Function With Echo and BNP in Obstetrical Patients With/Without Cardiac Disease
Prospective Cohort Evaluation of Cardiac Function With Echocardiography and Serum B-type Natriuretic Peptide (BNP) in Obstetrical Patients With and Without a History of Cardiac Disease
Status: Enrolling
Updated:  8/4/2010
Regional Perinatal Center
mi
from
Syracuse, NY
Evaluation Cardiac Function With Echo and BNP in Obstetrical Patients With/Without Cardiac Disease
Prospective Cohort Evaluation of Cardiac Function With Echocardiography and Serum B-type Natriuretic Peptide (BNP) in Obstetrical Patients With and Without a History of Cardiac Disease
Status: Enrolling
Updated: 8/4/2010
Regional Perinatal Center
mi
from
Syracuse, NY
Click here to add this to my saved trials
Evaluation Cardiac Function With Echo and BNP in Obstetrical Patients With/Without Cardiac Disease
Prospective Cohort Evaluation of Cardiac Function With Echocardiography and Serum B-type Natriuretic Peptide (BNP) in Obstetrical Patients With and Without a History of Cardiac Disease
Status: Enrolling
Updated:  8/4/2010
Cardiology Associates Central New York Physician Office Building
mi
from
Syracuse, NY
Evaluation Cardiac Function With Echo and BNP in Obstetrical Patients With/Without Cardiac Disease
Prospective Cohort Evaluation of Cardiac Function With Echocardiography and Serum B-type Natriuretic Peptide (BNP) in Obstetrical Patients With and Without a History of Cardiac Disease
Status: Enrolling
Updated: 8/4/2010
Cardiology Associates Central New York Physician Office Building
mi
from
Syracuse, NY
Click here to add this to my saved trials
Cardiovascular Disease Education and Problem-Solving Training in People With Type 2 Diabetes
Randomized Trial of CVD Education and Problem-Solving Training in Urban Diabetics
Status: Enrolling
Updated:  8/17/2010
Johns Hopkins School of Medicine/General Internal Medicine
mi
from
Baltimore, MD
Cardiovascular Disease Education and Problem-Solving Training in People With Type 2 Diabetes
Randomized Trial of CVD Education and Problem-Solving Training in Urban Diabetics
Status: Enrolling
Updated: 8/17/2010
Johns Hopkins School of Medicine/General Internal Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cardiovascular Disease Education and Problem-Solving Training in People With Type 2 Diabetes
Randomized Trial of CVD Education and Problem-Solving Training in Urban Diabetics
Status: Enrolling
Updated:  8/17/2010
Johns Hopkins School of Medicine/General Clinical Research Center
mi
from
Baltimore, MD
Cardiovascular Disease Education and Problem-Solving Training in People With Type 2 Diabetes
Randomized Trial of CVD Education and Problem-Solving Training in Urban Diabetics
Status: Enrolling
Updated: 8/17/2010
Johns Hopkins School of Medicine/General Clinical Research Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cardiovascular Disease Education and Problem-Solving Training in People With Type 2 Diabetes
Randomized Trial of CVD Education and Problem-Solving Training in Urban Diabetics
Status: Enrolling
Updated:  8/17/2010
Johns Hopkins Bayview Medical Center/General Clinical Research Center
mi
from
Baltimore, MD
Cardiovascular Disease Education and Problem-Solving Training in People With Type 2 Diabetes
Randomized Trial of CVD Education and Problem-Solving Training in Urban Diabetics
Status: Enrolling
Updated: 8/17/2010
Johns Hopkins Bayview Medical Center/General Clinical Research Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated:  9/1/2010
Cardiology PC
mi
from
Birmingham, AL
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated: 9/1/2010
Cardiology PC
mi
from
Birmingham, AL
Click here to add this to my saved trials
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated:  9/1/2010
Arizona Heart Institute
mi
from
Phoenix, AZ
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated: 9/1/2010
Arizona Heart Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated:  9/1/2010
Mayo Clinic Hospital
mi
from
Phoenix, AZ
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated: 9/1/2010
Mayo Clinic Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated:  9/1/2010
Scripps Green Hospital / Scripps Clinical Hospital
mi
from
La Jolla, CA
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated: 9/1/2010
Scripps Green Hospital / Scripps Clinical Hospital
mi
from
La Jolla, CA
Click here to add this to my saved trials
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated:  9/1/2010
Stanford Hospitals and Clinics
mi
from
Stanford, CA
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated: 9/1/2010
Stanford Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated:  9/1/2010
MedStar Washington Hospital Center
mi
from
Washington,
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated: 9/1/2010
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated:  9/1/2010
Holy Cross Hospital
mi
from
Ft. Lauderdale, FL
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated: 9/1/2010
Holy Cross Hospital
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated:  9/1/2010
University of Florida
mi
from
Gainesville, FL
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated: 9/1/2010
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated:  9/1/2010
Shands Jacksonville Medical Center
mi
from
Jacksonville, FL
ACT34-CMI -- Adult Autologous CD34+ Stem Cells
A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status: Enrolling
Updated: 9/1/2010
Shands Jacksonville Medical Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials